Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Progress in the understanding of the protein C anticoagulant pathway.

In English

Författare

Summary, in English

A natural anticoagulant pathway denoted the protein C system provides specific and efficient control of blood coagulation. Protein C is the key component of the system and circulates in the blood as a zymogen to an anticoagulant serine protease.Activation of protein C is achieved on the surface of endothelial cells by thrombin bound to the membrane protein thrombomodulin. The endothelial protein C receptor stimulates the activation of protein C on the endothelium. Activated protein C (APC) modulates blood coagulation by cleaving a limited number of peptide bonds in factor VIIIa (FVIIIa) and factor Va (FVa), cofactors in the activation of factor X and prothrombin, respectively.Vitamin K-dependent protein S stimulates the APC-mediated regulation of coagulation. Not only is protein S involved in the degradation of FVIIIa, but so is FV, which in recent years has been found to be a Janus-faced protein with both procoagulant and anticoagulant potentials.A number of genetic defects affecting the anticoagulant function of the protein C system, eg,APC resistance (Arg506Gln or FV Leiden) and deficiencies of protein C and protein S constitute major risk factors of venous thrombosis.The protein C system also has anti-inflammatory and antiapoptotic potentials,the molecular mechanisms of which are beginning to be unraveled.APC has emerged in recent years as a useful therapeutic compound in the treatment of severe septic shock.The beneficial effect of APC is believed be due to both its anticoagulant and its anti-inflammatory properties.

Publiceringsår

2004

Språk

Engelska

Sidor

109-116

Publikation/Tidskrift/Serie

International Journal of Hematology

Volym

79

Issue

2

Dokumenttyp

Artikel i tidskrift

Förlag

Springer

Ämne

  • Medicinal Chemistry

Status

Published

Forskningsgrupp

  • Clinical Chemistry, Malmö

ISBN/ISSN/Övrigt

  • ISSN: 0925-5710